Actively Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2025-12-23
248
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer
CONDITIONS
Official Title
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to give informed consent and comply with treatment and study procedures
- Age between 18 and 70 years, any gender
- Provide archived or fresh tumor tissue for testing
- At least one measurable tumor lesion per RECIST v1.1 criteria
- Diagnosed with locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology, inoperable and not suitable for radical radiotherapy or chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival of at least 12 weeks
- Adequate organ function
- Use of highly effective contraception for males with partners of childbearing potential and for fertile females
You will not qualify if you...
- Active or symptomatic brain metastases
- Other malignancies unless in complete remission for at least 5 years and considered cured
- Uncontrolled moderate to large pleural, peritoneal, or pericardial effusion
- Uncontrolled tumor-related pain
- Antitumor therapy received within 4 weeks prior to study start
- Non-chest radiation therapy over 30 Gy within 28 days before dosing, chest radiation over 30 Gy within 24 weeks before dosing, or any radiation therapy within 14 days before dosing
- Participation in another clinical trial with recent dosing within 4 weeks or within 5 half-lives of prior investigational drug
- Recent major or elective surgery within specified timeframes
- Ongoing toxicity from previous antitumor therapy above mild level
- Systemic immunosuppressive therapy within 14 days before study
- History or current interstitial/non-infectious pneumonia requiring treatment
- Active or suspected autoimmune disease
- Severe cardiovascular or cerebrovascular disease
- Severe infection within 28 days before first dose
- Active hepatitis B or C
- Active pulmonary tuberculosis within 1 year
- Significant bleeding within 1 month
- History of immune deficiency
- Use of live attenuated vaccines within 28 days before or during study
- Pregnancy or planning pregnancy during study
- Uncontrollable mental illness or substance abuse
- Any conditions increasing study risk or interfering with results per investigator judgment
- Bleeding disorders or high bleeding risk (for patients using bevacizumab)
- Poorly controlled hypertension or history of hypertensive crisis (for bevacizumab patients)
- Major vascular disease within 6 months (for bevacizumab patients)
- Use of anticoagulants or platelet inhibitors shortly before dosing (for bevacizumab patients)
- Severe untreated wounds, ulcers, fractures, or history of gastrointestinal perforation (for bevacizumab patients)
- Tumor involvement of major blood vessels (for bevacizumab patients)
- Prior systemic anti-angiogenic treatment including VEGF/VEGFR inhibitors (for bevacizumab patients)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Y
Yunfei Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here